Open AccessEvaluation of the use, effectiveness and safety of tyrosine kinase inhibitors in chronic myelogenous leukaemia in a general university hospital
Author(s) -
I Marquínez-Alonso,
Vicente EscuderoVilaplana,
Sonia Osorio,
Carmen Guadalupe Rodríguez-González,
Eva González-Haba,
María SanjurjoSáez
Publication year - 2018
Publication title -
european journal of hospital pharmacy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.313
H-Index - 14
eISSN - 2047-9964
pISSN - 2047-9956
DOI - 10.1136/ejhpharm-2017-001378
Subject(s) - nilotinib , dasatinib , medicine , imatinib , chronic myelogenous leukemia , tyrosine kinase , blast crisis , imatinib mesylate , adverse effect , tyrosine kinase inhibitor , oncology , pharmacology , leukemia , receptor , myeloid leukemia , cancer
To evaluate the use, effectiveness and safety of tyrosine kinase inhibitors (TKIs) for chronic myelogenous leukaemia (CML) in clinical practice.